Skip to main
INCY

Incyte (INCY) Stock Forecast & Price Target

Incyte (INCY) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 29%
Buy 29%
Hold 36%
Sell 7%
Strong Sell 0%

Bulls say

Incyte's financial outlook is bolstered by a 10% year-over-year growth in Jakafi demand across all indications, along with a successful commercial launch of Niktivmo contributing to revenue increases. The firm raised its fiscal year 2025 revenue guidance to between $4.23 billion and $4.32 billion, primarily driven by strong projections for Jakafi and other oncology products, which are now expected to generate $550 million to $575 million. Additionally, the positive market sentiment surrounding Incyte, reflected in a 29% stock increase over the past three months, is supported by robust commercial execution, a positive management shift, and promising clinical results from product pipelines.

Bears say

Incyte's stock outlook appears negative due to several critical risks impacting its financial stability. Primarily, there are concerns regarding eroding pricing power for Jakafi, compounded by poor performance in the earlier-stage pipeline, which could negatively affect future revenue streams. Additionally, potential clinical or regulatory setbacks for Jakafi combinations and adverse market dynamics, including increased competition and reimbursement challenges, heighten the downside risk for the company's overall valuation.

Incyte (INCY) has been analyzed by 14 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 29% recommend Buy, 36% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Incyte (INCY) Forecast

Analysts have given Incyte (INCY) a Buy based on their latest research and market trends.

According to 14 analysts, Incyte (INCY) has a Buy consensus rating as of Dec 31, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $99.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $99.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Incyte (INCY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.